Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH ALL 2021 | Current trials of non-cytotoxic therapies for older ALL

Selina Luger • 14 May 2021
ESH ALL 2021
Acute Lymphoblastic Leukemia Leukemia Blinatumomab Dasatinib Hyper-CVAD Inotuzumab ozogamicin Venetoclax

Selina Luger, MD, University of Pennsylvania, Philadelphia, PA, gives an update on current trials investigating the effectiveness of non-cytotoxic therapies for treating elderly patients with acute lymphoblastic leukemia (ALL). These therapies include inotuzumab, venetoclax, blinatumomab and dasatinib. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.

More from Selina Luger

Challenges with a new clinical trial design for AML that uses biomarker-driven endpoints
1:41
Challenges with a new clinical trial design for AML that uses biomarker-driven endpoints
Selina Luger • 18 Mar 2025
An innovative approach to AML clinical trial design
2:51
An innovative approach to AML clinical trial design
Selina Luger • 18 Mar 2025
Results of a Phase II study of gilteritinib versus midostaurin in newly diagnosed FLT3-mutated AML
5:59
Results of a Phase II study of gilteritinib versus midostaurin in newly diagnosed FLT3-mutated AML
Selina Luger • 6 Dec 2024
Determining the optimal dose of induction therapy for patients with AML
5:22
Determining the optimal dose of induction therapy for patients with AML
Selina Luger • 6 Oct 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals